Europe Nuclear Medicine Market

The Europe nuclear medicine market is projected to reach USD 5.15 billion by 2030 from USD 2.47 billion in 2025, at a CAGR of 15.8% during the forecast period. The rising application of radiopharmaceuticals and radioisotopes in oncology, cardiology, and neurology contributes to the market growth because of a growing population of the elderly and a growing burden of cancer in Europe. The market is also growing with the increasing use of PET and SPECT diagnostics & the rising demand for therapeutic radioisotopes, including lutetium-177. Additionally, strong healthcare infrastructure, research investments & funding, and supportive regulatory environments in the European Union are enhancing the production, research, and clinical adoption of nuclear medicine solutions.

In the Europe nuclear medicine (radiopharmaceuticals/radioisotopes) market, participants are focusing on strengthening control over the radiopharmaceutical supply chain through an increase in the number of in-house generation and regional production capabilities to secure stable assurance of the essential supply of radioisotopes. Companies like Curium have been aggressively investing in the PET radiopharmaceutical manufacturing and distribution infrastructure in Europe to meet the increasing diagnostic and therapeutic markets. Additionally, the market players are seeking strategic partnerships, acquisitions, and long-term isotope supply contracts to expand their nuclear medicine and theranostics platforms and increase their geographic coverage, and companies such as GE HealthCare and Bayer have followed this strategy to accelerate innovation and improve their competitive positions in the European market.

To know about the assumptions considered for the study download the pdf brochure

Prominent players in the market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), Sun Pharmaceutical Industries, Inc. (India), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radiosiotopes, LLC (US), Eckert & Ziegler (Germany), Medi-Radiopharma (Hungary), SHINE Technologies, LLC (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), Isotopia (Israel), Institutes of Isotopes (Hungary), IRE Elit (Turkey), Cyclopharm (Australia), RadioMedix, Inc. (US).

In the European nuclear medicine market, GE HealthCare operates through its Pharmaceutical Diagnostics business, which distributes radiopharmaceuticals and associated solutions to support imaging in neurology, cardiology, and oncology by SPECT and PET. Its portfolio includes approved nuclear imaging agents, radiochemistry systems, and cyclotron-related technologies involved in the manufacturing and management of radioisotopes in hospital-based and commercial radiopharmacies. GE HealthCare serves major markets in Europe by offering hospitals and diagnostic centers a range of products and services through regional manufacturing, regulatory operations, and distribution facilities.

Cardinal Health is involved in the European nuclear medicine market through its Nuclear and Precision Health Solutions (NPHS) unit, which produces, prepares, and distributes radiopharmaceuticals and radioisotope products used in diagnostic imaging (e.g., PET and SPECT) and in emerging theranostic applications. The company's offerings include access to a wide range of imaging agents and other related services that facilitate clinical activities in hospitals and imaging centers, as well as contract manufacturing and radiopharmacy services. Cardinal Health uses its global supply chain and logistics operations in Europe to serve its customers in Europe in addition to those served in North America and other regions.

MARKET RANKING

Experienced radiopharmaceutical developers and healthcare companies are facilitating the Europe nuclear medicine market, and they focus on regional production, cross-border distribution, and clinical collaboration in the field of oncology, cardiology, and neurology. GE HealthCare has a strong presence in Europe due to its large portfolio of PET and SPECT radiopharmaceuticals and strategic investment in cyclotron infrastructure and alliances with hospitals, which ensures the uniform availability of tracers in major European nations. Cardinal Health plays its role in providing nuclear medicine products and consumables and operational support to European nuclear medicine departments, enhancing workflow productivity and adherence. Curium Pharma is at the center stage of production of Europe-based radioisotopes, PET manufacturing facilities, and a radiopharmacy network with a focus on both diagnostic imaging and targeted radionuclide therapy requirements. Bayer has stable diagnostic imaging agents and is active in nuclear imaging applications with oncology and cardiovascular segments of the market. These companies, as a whole, strengthen the European nuclear medicine ecosystem, improving the availability of radiotracers, the reliability of their distribution, clinical use, and imaging.

Related Reports:

"Europe Nuclear Medicine Market by Type (SPECT [Tc99m, I-123], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90, I-131], Brachytherapy), Application (Onco, Cardio), Procedure, End User (Imaging Center, Hospital), Market Growth - Forecast to 2030"

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]